Quince Therapeutics (QNCX) Expected to Announce Earnings on Monday

Quince Therapeutics (NASDAQ:QNCX) is anticipated to release its earnings data before the market opens on Monday, April 7th. Analysts expect Quince Therapeutics to post earnings of ($0.10) per share for the quarter.

Quince Therapeutics (NASDAQ:QNCX) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.09). The company had revenue of $0.17 million for the quarter. On average, analysts expect Quince Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quince Therapeutics Stock Down 3.6 %

Shares of NASDAQ QNCX opened at $1.35 on Monday. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. The stock has a market cap of $59.40 million, a P/E ratio of -1.09 and a beta of 0.71. The firm has a 50 day moving average price of $1.47 and a 200 day moving average price of $1.46.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on QNCX shares. Brookline Capital Management initiated coverage on shares of Quince Therapeutics in a report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price target for the company. D. Boral Capital reduced their target price on Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, March 25th. Finally, Oppenheimer began coverage on Quince Therapeutics in a report on Monday, March 24th. They issued an “outperform” rating and a $10.00 price target for the company. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $8.00.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.